Dr. David S Shulman, MD
Claim this profileDana Farber Cancer Institute
Studies Osteosarcoma
Studies Ewing Sarcoma
4 reported clinical trials
7 drugs studied
Area of expertise
1Osteosarcoma
Stage IV
FET-ETS family translocation positive
EWSR1::WT1 fusion positive
2Ewing Sarcoma
Stage IV
FET-ETS family translocation positive
EWSR1::WT1 fusion positive
Affiliated Hospitals
Clinical Trials David S Shulman, MD is currently running
PEEL-224 + Vincristine + Temozolomide
for Sarcoma
This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (DSRCT), as well as multiple other kinds of sarcomas. The names of the study drugs and biological agents involved in this study are: * PEEL-224 (a type of Topoisomerase 1 inhibitor) * Vincristine (A type of vinca alkaloid) * Temozolomide (A type of alkylating agent) * Pegfilgrastim or Filgrastim (types of Myeloid growth factors)
Recruiting1 award Phase 1 & 28 criteria
Liquid Biopsy
for Bone Cancer
This trial is testing a blood test that looks for small pieces of tumor DNA in patients with Ewing sarcoma or osteosarcoma. The goal is to see if this test can help predict if the cancer will return after treatment. A group of patients will participate to help researchers understand how useful this test can be.
Recruiting1 award N/A15 criteria
More about David S Shulman, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David S Shulman, MD has experience with
- FoundationOne Liquid CDx
- PEEL-224
- Temozolomide
- Vincristine
- ALRN-6924
- Cytarabine
Breakdown of trials David S Shulman, MD has run
Lymphoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David S Shulman, MD specialize in?
David S Shulman, MD focuses on Osteosarcoma and Ewing Sarcoma. In particular, much of their work with Osteosarcoma has involved Stage IV patients, or patients who are FET-ETS family translocation positive.
Is David S Shulman, MD currently recruiting for clinical trials?
Yes, David S Shulman, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that David S Shulman, MD has studied deeply?
Yes, David S Shulman, MD has studied treatments such as FoundationOne Liquid CDx, PEEL-224, Temozolomide.
What is the best way to schedule an appointment with David S Shulman, MD?
Apply for one of the trials that David S Shulman, MD is conducting.
What is the office address of David S Shulman, MD?
The office of David S Shulman, MD is located at: Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States. This is the address for their practice at the Dana Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.